A Study of LAM-003 in Patients With Acute Myeloid Leukemia

Completed · Phase 1

Conditions studied: Oncology, Acute Myeloid Leukemia

In brief

A Phase 1 Dose-Escalation Study of LAM-003 in Patients with Acute Myeloid Leukemia

Key facts

Study ID

NCT03426605

Run by

OrphAI Therapeutics

People needed

17

Starts

2018-01-16

Expected to finish

2020-10-05

Last updated by the study team

2024-05-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Men and women of age ≥18 years.
• Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.
• Presence of measurable AML that has progressed during or relapsed after prior therapy
• All acute toxic effects of any prior antitumor therapy resolved to Grade 1.
• Adequate hepatic profile.
• Adequate renal function.
• Adequate coagulation profile.
• Negative antiviral serology for human immunodeficiency virus (HIV), hepatitis B, and hepatitis C.
• For female subjects of childbearing potential, a negative serum pregnancy test.
• For both male and female subjects, willingness to use adequate contraception.
• Willingness and ability of the subject to comply with study activities.
• Evidence of a personally signed informed consent document.

You may not qualify if…

• Leukemic blast cell count >50 × 10\^9/L before the start of study therapy and despite the use hydroxyurea, cytarabine, and/or cyclophosphamide.
• Presence of known central nervous system (CNS) leukemia.
• Presence of another major cancer.
• Ongoing Grade >1 proliferative or nonproliferative retinopathy.
• Significant cardiovascular disease or ECG abnormalities.
• Significant gastrointestinal disease
• Uncontrolled ongoing infection.
• Pregnancy or breastfeeding.
• Major surgery within 4 weeks before the start of study therapy.
• Subject was a candidate for hematopoietic stem cell transplantation (HSCT).
• Ongoing severe graft-versus-house disease (GVHD) with Grade ≥2 serum bilirubin, Grade ≥3 skin involvement, or Grade ≥3 diarrhea at the start of study therapy.
• Prior solid organ transplantation.
• Ongoing immunosuppressive therapy other than corticosteroids.
• Use of a strong inhibitor or inducer of cytochrome P450 (CYP) 3A4.
• Use of a drug known to prolong the cardiac QT interval.
• Concurrent participation in another therapeutic or imaging clinical trial.
• Presence of a concomitant medical condition that (in the judgement of the investigator) interferes with the ability of the subject to participate in the study.

Where it is running

• Yale University — New Haven, Connecticut, United States
• University of Maryland — Baltimore, Maryland, United States
• Dana Farber Cancer Institute — Boston, Massachusetts, United States
• Hackensack Meridien Health — Hackensack, New Jersey, United States
• Weill Cornell Medical College — New York, New York, United States
• Virginia Cancer Specialists — Fairfax, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.